CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS
We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results. 1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4g/day of CBPZ...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of antibiotics 1988/03/25, Vol.41(3), pp.322-330 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 330 |
|---|---|
| container_issue | 3 |
| container_start_page | 322 |
| container_title | Japanese journal of antibiotics |
| container_volume | 41 |
| creator | KAI, HIDENOBU SUGIMACHI, KEIZO TAMADA, RYUICHIRO TAKENAKA, KENJI INUZUKA, SADAMITSU NATSUDA, YASUNORI TAGUCHI, JUNICHI KOBAYASHI, MICHIO KANEKO, TAKASHI MITARAI, YOSHINOBU KAKISAKO, KENJI TSUJI, HIDEO ABE, RYOJI WADA, TETSUYA FURUSAWA, MOTONOSUKE TOMODA, HIROTSUGU SAKU, MOTONORI FURUYAMA, MASATO HARAGUCHI, YUKIAKI KUWANO, HIROYUKI TOH, YASUSHI MINE, HIROYUKI IKEDA, TOSHIHIKO KUMA, HIROMASA SAKATO, KAZUHIDE NAKAYAMA, SHINNCHI OOWAKI, YOSHITO MINAGAWA, SEIZO TATEISHI, HARUO MORIYAMA, MASAAKI MORI, AKIRA SAKATA, HISANOBU OKA, NAOKATA NODA, SHOOCHI KOGA, SHUNROKU |
| description | We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results. 1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4g/day of CBPZ (87.5%, 14/16) than in those who were given 2g/day (57.1%, 8/14). 2) Antibacterial activity of CBPZ was evaluated in 41 isolated bacterial strains. Pathogen eradication rate by bacterial species was 75.6% (31/41). CBPZ exerted excellent antibacterial effects on Escherichia coli (100%, 8/8) and anaerobic bacteria such as Bacteroides (88.9%, 8/9). Resistant bacteria to CBPZ were Enterococcus faecalis and Pseudomonas aeruginosa. 3) No serious side effects were noted in any of the 34 patients who entered in this study. Abnormal laboratory test results were noted in 2 patients (5.9%) and they were transient elevation of transaminases and alkaline phosphatase. From the results shown above, CBPZ appears to be a highly useful antibiotic for the treatment of surgical infection. |
| doi_str_mv | 10.11553/antibiotics1968b.41.322 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_jstag</sourceid><recordid>TN_cdi_pubmed_primary_3043033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3043033</sourcerecordid><originalsourceid>FETCH-LOGICAL-j188t-f53e0ed1ec53418770831766c5cfc075768070b207d893aa5f1d01349b82aba63</originalsourceid><addsrcrecordid>eNpdkE1vgkAQhjdNG2usP6EJfwC7s8N-eFQKLY2BRuTSC9mFpcWoNUAP_fdFNB56mTk8T97MvIQ4QGcAnOOTPnS1qb-7umhhLpSZeTBDxm7ImIESLvekvCVjikK5TCq4J9O2rQ1FkIr1CSMyQuohRRyTpb-K4shfrJx0kz1HQeoksROEYeBvnCR0_CBcZu_BevGRxMEJpdn6ZdCj-ORESZw-kLtK71o7vewJycJg47-6q2RQ3S0o1bkVR0ttCbbg6IGSkqr-ICEKXlQFlVwKRSU1jMpSzVFrXkFJAb25UUwbLXBCHs-5xx-zt2V-bOq9bn7zyy89fzvzbdvpT3vluumL2tn8f2u5BzkOg7GrVHzpJrcH_APYAGOA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KAI, HIDENOBU ; SUGIMACHI, KEIZO ; TAMADA, RYUICHIRO ; TAKENAKA, KENJI ; INUZUKA, SADAMITSU ; NATSUDA, YASUNORI ; TAGUCHI, JUNICHI ; KOBAYASHI, MICHIO ; KANEKO, TAKASHI ; MITARAI, YOSHINOBU ; KAKISAKO, KENJI ; TSUJI, HIDEO ; ABE, RYOJI ; WADA, TETSUYA ; FURUSAWA, MOTONOSUKE ; TOMODA, HIROTSUGU ; SAKU, MOTONORI ; FURUYAMA, MASATO ; HARAGUCHI, YUKIAKI ; KUWANO, HIROYUKI ; TOH, YASUSHI ; MINE, HIROYUKI ; IKEDA, TOSHIHIKO ; KUMA, HIROMASA ; SAKATO, KAZUHIDE ; NAKAYAMA, SHINNCHI ; OOWAKI, YOSHITO ; MINAGAWA, SEIZO ; TATEISHI, HARUO ; MORIYAMA, MASAAKI ; MORI, AKIRA ; SAKATA, HISANOBU ; OKA, NAOKATA ; NODA, SHOOCHI ; KOGA, SHUNROKU</creator><creatorcontrib>KAI, HIDENOBU ; SUGIMACHI, KEIZO ; TAMADA, RYUICHIRO ; TAKENAKA, KENJI ; INUZUKA, SADAMITSU ; NATSUDA, YASUNORI ; TAGUCHI, JUNICHI ; KOBAYASHI, MICHIO ; KANEKO, TAKASHI ; MITARAI, YOSHINOBU ; KAKISAKO, KENJI ; TSUJI, HIDEO ; ABE, RYOJI ; WADA, TETSUYA ; FURUSAWA, MOTONOSUKE ; TOMODA, HIROTSUGU ; SAKU, MOTONORI ; FURUYAMA, MASATO ; HARAGUCHI, YUKIAKI ; KUWANO, HIROYUKI ; TOH, YASUSHI ; MINE, HIROYUKI ; IKEDA, TOSHIHIKO ; KUMA, HIROMASA ; SAKATO, KAZUHIDE ; NAKAYAMA, SHINNCHI ; OOWAKI, YOSHITO ; MINAGAWA, SEIZO ; TATEISHI, HARUO ; MORIYAMA, MASAAKI ; MORI, AKIRA ; SAKATA, HISANOBU ; OKA, NAOKATA ; NODA, SHOOCHI ; KOGA, SHUNROKU</creatorcontrib><description>We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results. 1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4g/day of CBPZ (87.5%, 14/16) than in those who were given 2g/day (57.1%, 8/14). 2) Antibacterial activity of CBPZ was evaluated in 41 isolated bacterial strains. Pathogen eradication rate by bacterial species was 75.6% (31/41). CBPZ exerted excellent antibacterial effects on Escherichia coli (100%, 8/8) and anaerobic bacteria such as Bacteroides (88.9%, 8/9). Resistant bacteria to CBPZ were Enterococcus faecalis and Pseudomonas aeruginosa. 3) No serious side effects were noted in any of the 34 patients who entered in this study. Abnormal laboratory test results were noted in 2 patients (5.9%) and they were transient elevation of transaminases and alkaline phosphatase. From the results shown above, CBPZ appears to be a highly useful antibiotic for the treatment of surgical infection.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.41.322</identifier><identifier>PMID: 3043033</identifier><language>jpn</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Adult ; Aged ; Bacteria - isolation & purification ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Cephamycins - administration & dosage ; Cephamycins - adverse effects ; Cephamycins - therapeutic use ; Clinical Trials as Topic ; Female ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Postoperative Complications - drug therapy ; Postoperative Complications - microbiology</subject><ispartof>The Japanese Journal of Antibiotics, 1988/03/25, Vol.41(3), pp.322-330</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3043033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KAI, HIDENOBU</creatorcontrib><creatorcontrib>SUGIMACHI, KEIZO</creatorcontrib><creatorcontrib>TAMADA, RYUICHIRO</creatorcontrib><creatorcontrib>TAKENAKA, KENJI</creatorcontrib><creatorcontrib>INUZUKA, SADAMITSU</creatorcontrib><creatorcontrib>NATSUDA, YASUNORI</creatorcontrib><creatorcontrib>TAGUCHI, JUNICHI</creatorcontrib><creatorcontrib>KOBAYASHI, MICHIO</creatorcontrib><creatorcontrib>KANEKO, TAKASHI</creatorcontrib><creatorcontrib>MITARAI, YOSHINOBU</creatorcontrib><creatorcontrib>KAKISAKO, KENJI</creatorcontrib><creatorcontrib>TSUJI, HIDEO</creatorcontrib><creatorcontrib>ABE, RYOJI</creatorcontrib><creatorcontrib>WADA, TETSUYA</creatorcontrib><creatorcontrib>FURUSAWA, MOTONOSUKE</creatorcontrib><creatorcontrib>TOMODA, HIROTSUGU</creatorcontrib><creatorcontrib>SAKU, MOTONORI</creatorcontrib><creatorcontrib>FURUYAMA, MASATO</creatorcontrib><creatorcontrib>HARAGUCHI, YUKIAKI</creatorcontrib><creatorcontrib>KUWANO, HIROYUKI</creatorcontrib><creatorcontrib>TOH, YASUSHI</creatorcontrib><creatorcontrib>MINE, HIROYUKI</creatorcontrib><creatorcontrib>IKEDA, TOSHIHIKO</creatorcontrib><creatorcontrib>KUMA, HIROMASA</creatorcontrib><creatorcontrib>SAKATO, KAZUHIDE</creatorcontrib><creatorcontrib>NAKAYAMA, SHINNCHI</creatorcontrib><creatorcontrib>OOWAKI, YOSHITO</creatorcontrib><creatorcontrib>MINAGAWA, SEIZO</creatorcontrib><creatorcontrib>TATEISHI, HARUO</creatorcontrib><creatorcontrib>MORIYAMA, MASAAKI</creatorcontrib><creatorcontrib>MORI, AKIRA</creatorcontrib><creatorcontrib>SAKATA, HISANOBU</creatorcontrib><creatorcontrib>OKA, NAOKATA</creatorcontrib><creatorcontrib>NODA, SHOOCHI</creatorcontrib><creatorcontrib>KOGA, SHUNROKU</creatorcontrib><title>CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results. 1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4g/day of CBPZ (87.5%, 14/16) than in those who were given 2g/day (57.1%, 8/14). 2) Antibacterial activity of CBPZ was evaluated in 41 isolated bacterial strains. Pathogen eradication rate by bacterial species was 75.6% (31/41). CBPZ exerted excellent antibacterial effects on Escherichia coli (100%, 8/8) and anaerobic bacteria such as Bacteroides (88.9%, 8/9). Resistant bacteria to CBPZ were Enterococcus faecalis and Pseudomonas aeruginosa. 3) No serious side effects were noted in any of the 34 patients who entered in this study. Abnormal laboratory test results were noted in 2 patients (5.9%) and they were transient elevation of transaminases and alkaline phosphatase. From the results shown above, CBPZ appears to be a highly useful antibiotic for the treatment of surgical infection.</description><subject>Adult</subject><subject>Aged</subject><subject>Bacteria - isolation & purification</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Cephamycins - administration & dosage</subject><subject>Cephamycins - adverse effects</subject><subject>Cephamycins - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Postoperative Complications - drug therapy</subject><subject>Postoperative Complications - microbiology</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1vgkAQhjdNG2usP6EJfwC7s8N-eFQKLY2BRuTSC9mFpcWoNUAP_fdFNB56mTk8T97MvIQ4QGcAnOOTPnS1qb-7umhhLpSZeTBDxm7ImIESLvekvCVjikK5TCq4J9O2rQ1FkIr1CSMyQuohRRyTpb-K4shfrJx0kz1HQeoksROEYeBvnCR0_CBcZu_BevGRxMEJpdn6ZdCj-ORESZw-kLtK71o7vewJycJg47-6q2RQ3S0o1bkVR0ttCbbg6IGSkqr-ICEKXlQFlVwKRSU1jMpSzVFrXkFJAb25UUwbLXBCHs-5xx-zt2V-bOq9bn7zyy89fzvzbdvpT3vluumL2tn8f2u5BzkOg7GrVHzpJrcH_APYAGOA</recordid><startdate>198803</startdate><enddate>198803</enddate><creator>KAI, HIDENOBU</creator><creator>SUGIMACHI, KEIZO</creator><creator>TAMADA, RYUICHIRO</creator><creator>TAKENAKA, KENJI</creator><creator>INUZUKA, SADAMITSU</creator><creator>NATSUDA, YASUNORI</creator><creator>TAGUCHI, JUNICHI</creator><creator>KOBAYASHI, MICHIO</creator><creator>KANEKO, TAKASHI</creator><creator>MITARAI, YOSHINOBU</creator><creator>KAKISAKO, KENJI</creator><creator>TSUJI, HIDEO</creator><creator>ABE, RYOJI</creator><creator>WADA, TETSUYA</creator><creator>FURUSAWA, MOTONOSUKE</creator><creator>TOMODA, HIROTSUGU</creator><creator>SAKU, MOTONORI</creator><creator>FURUYAMA, MASATO</creator><creator>HARAGUCHI, YUKIAKI</creator><creator>KUWANO, HIROYUKI</creator><creator>TOH, YASUSHI</creator><creator>MINE, HIROYUKI</creator><creator>IKEDA, TOSHIHIKO</creator><creator>KUMA, HIROMASA</creator><creator>SAKATO, KAZUHIDE</creator><creator>NAKAYAMA, SHINNCHI</creator><creator>OOWAKI, YOSHITO</creator><creator>MINAGAWA, SEIZO</creator><creator>TATEISHI, HARUO</creator><creator>MORIYAMA, MASAAKI</creator><creator>MORI, AKIRA</creator><creator>SAKATA, HISANOBU</creator><creator>OKA, NAOKATA</creator><creator>NODA, SHOOCHI</creator><creator>KOGA, SHUNROKU</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198803</creationdate><title>CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS</title><author>KAI, HIDENOBU ; SUGIMACHI, KEIZO ; TAMADA, RYUICHIRO ; TAKENAKA, KENJI ; INUZUKA, SADAMITSU ; NATSUDA, YASUNORI ; TAGUCHI, JUNICHI ; KOBAYASHI, MICHIO ; KANEKO, TAKASHI ; MITARAI, YOSHINOBU ; KAKISAKO, KENJI ; TSUJI, HIDEO ; ABE, RYOJI ; WADA, TETSUYA ; FURUSAWA, MOTONOSUKE ; TOMODA, HIROTSUGU ; SAKU, MOTONORI ; FURUYAMA, MASATO ; HARAGUCHI, YUKIAKI ; KUWANO, HIROYUKI ; TOH, YASUSHI ; MINE, HIROYUKI ; IKEDA, TOSHIHIKO ; KUMA, HIROMASA ; SAKATO, KAZUHIDE ; NAKAYAMA, SHINNCHI ; OOWAKI, YOSHITO ; MINAGAWA, SEIZO ; TATEISHI, HARUO ; MORIYAMA, MASAAKI ; MORI, AKIRA ; SAKATA, HISANOBU ; OKA, NAOKATA ; NODA, SHOOCHI ; KOGA, SHUNROKU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j188t-f53e0ed1ec53418770831766c5cfc075768070b207d893aa5f1d01349b82aba63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Bacteria - isolation & purification</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Cephamycins - administration & dosage</topic><topic>Cephamycins - adverse effects</topic><topic>Cephamycins - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Postoperative Complications - drug therapy</topic><topic>Postoperative Complications - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KAI, HIDENOBU</creatorcontrib><creatorcontrib>SUGIMACHI, KEIZO</creatorcontrib><creatorcontrib>TAMADA, RYUICHIRO</creatorcontrib><creatorcontrib>TAKENAKA, KENJI</creatorcontrib><creatorcontrib>INUZUKA, SADAMITSU</creatorcontrib><creatorcontrib>NATSUDA, YASUNORI</creatorcontrib><creatorcontrib>TAGUCHI, JUNICHI</creatorcontrib><creatorcontrib>KOBAYASHI, MICHIO</creatorcontrib><creatorcontrib>KANEKO, TAKASHI</creatorcontrib><creatorcontrib>MITARAI, YOSHINOBU</creatorcontrib><creatorcontrib>KAKISAKO, KENJI</creatorcontrib><creatorcontrib>TSUJI, HIDEO</creatorcontrib><creatorcontrib>ABE, RYOJI</creatorcontrib><creatorcontrib>WADA, TETSUYA</creatorcontrib><creatorcontrib>FURUSAWA, MOTONOSUKE</creatorcontrib><creatorcontrib>TOMODA, HIROTSUGU</creatorcontrib><creatorcontrib>SAKU, MOTONORI</creatorcontrib><creatorcontrib>FURUYAMA, MASATO</creatorcontrib><creatorcontrib>HARAGUCHI, YUKIAKI</creatorcontrib><creatorcontrib>KUWANO, HIROYUKI</creatorcontrib><creatorcontrib>TOH, YASUSHI</creatorcontrib><creatorcontrib>MINE, HIROYUKI</creatorcontrib><creatorcontrib>IKEDA, TOSHIHIKO</creatorcontrib><creatorcontrib>KUMA, HIROMASA</creatorcontrib><creatorcontrib>SAKATO, KAZUHIDE</creatorcontrib><creatorcontrib>NAKAYAMA, SHINNCHI</creatorcontrib><creatorcontrib>OOWAKI, YOSHITO</creatorcontrib><creatorcontrib>MINAGAWA, SEIZO</creatorcontrib><creatorcontrib>TATEISHI, HARUO</creatorcontrib><creatorcontrib>MORIYAMA, MASAAKI</creatorcontrib><creatorcontrib>MORI, AKIRA</creatorcontrib><creatorcontrib>SAKATA, HISANOBU</creatorcontrib><creatorcontrib>OKA, NAOKATA</creatorcontrib><creatorcontrib>NODA, SHOOCHI</creatorcontrib><creatorcontrib>KOGA, SHUNROKU</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KAI, HIDENOBU</au><au>SUGIMACHI, KEIZO</au><au>TAMADA, RYUICHIRO</au><au>TAKENAKA, KENJI</au><au>INUZUKA, SADAMITSU</au><au>NATSUDA, YASUNORI</au><au>TAGUCHI, JUNICHI</au><au>KOBAYASHI, MICHIO</au><au>KANEKO, TAKASHI</au><au>MITARAI, YOSHINOBU</au><au>KAKISAKO, KENJI</au><au>TSUJI, HIDEO</au><au>ABE, RYOJI</au><au>WADA, TETSUYA</au><au>FURUSAWA, MOTONOSUKE</au><au>TOMODA, HIROTSUGU</au><au>SAKU, MOTONORI</au><au>FURUYAMA, MASATO</au><au>HARAGUCHI, YUKIAKI</au><au>KUWANO, HIROYUKI</au><au>TOH, YASUSHI</au><au>MINE, HIROYUKI</au><au>IKEDA, TOSHIHIKO</au><au>KUMA, HIROMASA</au><au>SAKATO, KAZUHIDE</au><au>NAKAYAMA, SHINNCHI</au><au>OOWAKI, YOSHITO</au><au>MINAGAWA, SEIZO</au><au>TATEISHI, HARUO</au><au>MORIYAMA, MASAAKI</au><au>MORI, AKIRA</au><au>SAKATA, HISANOBU</au><au>OKA, NAOKATA</au><au>NODA, SHOOCHI</au><au>KOGA, SHUNROKU</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>1988-03</date><risdate>1988</risdate><volume>41</volume><issue>3</issue><spage>322</spage><epage>330</epage><pages>322-330</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results. 1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4g/day of CBPZ (87.5%, 14/16) than in those who were given 2g/day (57.1%, 8/14). 2) Antibacterial activity of CBPZ was evaluated in 41 isolated bacterial strains. Pathogen eradication rate by bacterial species was 75.6% (31/41). CBPZ exerted excellent antibacterial effects on Escherichia coli (100%, 8/8) and anaerobic bacteria such as Bacteroides (88.9%, 8/9). Resistant bacteria to CBPZ were Enterococcus faecalis and Pseudomonas aeruginosa. 3) No serious side effects were noted in any of the 34 patients who entered in this study. Abnormal laboratory test results were noted in 2 patients (5.9%) and they were transient elevation of transaminases and alkaline phosphatase. From the results shown above, CBPZ appears to be a highly useful antibiotic for the treatment of surgical infection.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>3043033</pmid><doi>10.11553/antibiotics1968b.41.322</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2781 |
| ispartof | The Japanese Journal of Antibiotics, 1988/03/25, Vol.41(3), pp.322-330 |
| issn | 0368-2781 2186-5477 |
| language | jpn |
| recordid | cdi_pubmed_primary_3043033 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Bacteria - isolation & purification Bacterial Infections - drug therapy Bacterial Infections - microbiology Cephamycins - administration & dosage Cephamycins - adverse effects Cephamycins - therapeutic use Clinical Trials as Topic Female Humans Infusions, Intravenous Male Middle Aged Postoperative Complications - drug therapy Postoperative Complications - microbiology |
| title | CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T15%3A14%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_jstag&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CLINICAL%20STUDIES%20ON%20EFFECT%20OF%20CEFBUPERAZONE%20ON%20SURGICAL%20INFECTIONS&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=KAI,%20HIDENOBU&rft.date=1988-03&rft.volume=41&rft.issue=3&rft.spage=322&rft.epage=330&rft.pages=322-330&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.41.322&rft_dat=%3Cpubmed_jstag%3E3043033%3C/pubmed_jstag%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3043033&rfr_iscdi=true |